Skip to main content
Explore URMC

menu

Colon Cancer: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Research Question:
What are the good and bad effects of using the drug atezolizumab along with the usual chemotherapy, FOLFOX, compared to the usual chemotherapy, FOLFOX, alone?

Basic Study Information

Purpose:
This study has 2 groups. Group 1 will receive the usual chemotherapy treatment of FOLFOX plus the drug atezolizumab for 6 months, then patients will take atezolizumab alone for an additional 6 months. Group 2 will receive the usual chemotherapy which is FOLFOX for 6 months.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/study/NCT02912559?term=A021502&rank=1&show_locs=Y#locn
Study Reference #: CGIC17112

Lead Researcher (Principal Investigator)

Lead Researcher: Mohamedtaki Tejani, MD

Study Contact Information

Study Coordinator: Tanya Smith
Phone: (585) 275-8213
Email: Tanya_Smith@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Colon Cancer

Return to Search